Global Eptacog Alfa (rFVIIa) Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Eptacog Alfa (rFVIIa) market size was valued at US$ 1353 million in 2024 and is forecast to a readjusted size of USD 1835 million by 2031 with a CAGR of 4.5% during review period.
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
This report is a detailed and comprehensive analysis for global Eptacog Alfa (rFVIIa) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Eptacog Alfa (rFVIIa) market size and forecasts, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2020-2031
Global Eptacog Alfa (rFVIIa) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2020-2031
Global Eptacog Alfa (rFVIIa) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2020-2031
Global Eptacog Alfa (rFVIIa) market shares of main players, shipments in revenue ($ Million), sales quantity (g), and ASP (US$/mg), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Eptacog Alfa (rFVIIa)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Eptacog Alfa (rFVIIa) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LFB SA, GENERIUM, Northland-bio, CSL, Shire (Takeda), Bayer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Eptacog Alfa (rFVIIa) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Market segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Major players covered
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eptacog Alfa (rFVIIa) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Eptacog Alfa (rFVIIa), with price, sales quantity, revenue, and global market share of Eptacog Alfa (rFVIIa) from 2020 to 2025.
Chapter 3, the Eptacog Alfa (rFVIIa) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eptacog Alfa (rFVIIa) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Eptacog Alfa (rFVIIa) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Eptacog Alfa (rFVIIa).
Chapter 14 and 15, to describe Eptacog Alfa (rFVIIa) sales channel, distributors, customers, research findings and conclusion.
Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Novo Nordisk is the largest manufacturers of eptacog alfa (rFVIIa) in the world, has a share about 92%. Other players include LFB SA, GENERIUM,Northland-bio, and Northland-bioi, etc. The key players are mainly located in Europe, North America, China, and Japan. In terms of product, freeze-dried preparation is the largest segment, with a share over 52%. And in terms of application, the largest application is hemophilia, with a share over 48%, followed by acquired hemophilia.
This report is a detailed and comprehensive analysis for global Eptacog Alfa (rFVIIa) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Eptacog Alfa (rFVIIa) market size and forecasts, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2020-2031
Global Eptacog Alfa (rFVIIa) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2020-2031
Global Eptacog Alfa (rFVIIa) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (g), and average selling prices (US$/mg), 2020-2031
Global Eptacog Alfa (rFVIIa) market shares of main players, shipments in revenue ($ Million), sales quantity (g), and ASP (US$/mg), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Eptacog Alfa (rFVIIa)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Eptacog Alfa (rFVIIa) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, LFB SA, GENERIUM, Northland-bio, CSL, Shire (Takeda), Bayer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Eptacog Alfa (rFVIIa) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Freeze-dried Preparation
Freeze-dried Powder
Market segment by Application
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Major players covered
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eptacog Alfa (rFVIIa) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Eptacog Alfa (rFVIIa), with price, sales quantity, revenue, and global market share of Eptacog Alfa (rFVIIa) from 2020 to 2025.
Chapter 3, the Eptacog Alfa (rFVIIa) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eptacog Alfa (rFVIIa) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Eptacog Alfa (rFVIIa) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Eptacog Alfa (rFVIIa).
Chapter 14 and 15, to describe Eptacog Alfa (rFVIIa) sales channel, distributors, customers, research findings and conclusion.
Table of Contents
100 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Eptacog Alfa (rFVIIa) by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
